Ampio Pharmaceuticals' (AMPE -6%) issues a statement intended to reassure shareholders about their plan to move to the NYSE, but it doesn't seem to be working. The response also attempted to address concerns raised in a Seeking Alpha blog entry recently posted by Greenwich Research that questions the stock's lofty valuation. AMPE states that the article "clearly intended to damage existing shareholders by triggering a downward pressure on their stock holdings."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs